This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y
by Zacks Equity Research
Iovance's shares jump 28% as the biotech narrows its quarterly loss and lifts gross margins amid strong Amtagvi sales and cost cuts.
ALKSPositive Net Change ANIPPositive Net Change CRMDNegative Net Change IOVANegative Net Change
biotechs earnings medical
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug
by Zacks Equity Research
Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.
BIIBNegative Net Change ALKSPositive Net Change DNLIPositive Net Change TAKPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Mettler-Toledo Q3 Earnings Top Estimates, Sales Decline Y/Y
by Zacks Equity Research
MTD posted stronger-than-expected Q3 results, lifted by segment growth and solid guidance for 2025 and 2026.
ALCNegative Net Change ADCTNegative Net Change MTDNegative Net Change AKBAPositive Net Change
artificial-intelligence earnings medical
AMN Stock Gains Following Q3 Earnings & Revenue Beat, Margins Down
by Zacks Equity Research
AMN Healthcare beats third-quarter 2025 earnings and revenue estimates despite lower margins and year-over-year declines across key segments.
BSXPositive Net Change AMNNegative Net Change WSTNegative Net Change EXASNegative Net Change
earnings medical medical-devices
Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care
by Debanjana Dey
HIMS expands its AI-powered, subscription-based care model globally, backed by $870 million in fresh funding for growth.
HIMSNegative Net Change LFMDNegative Net Change TEMNegative Net Change
medical medical-devices
Doximity Stock Down Despite Q2 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
DOCS Q2 results benefit from the rise in AI-driven engagement. However, the stock plunges nearly 9% in pre-market trading.
BSXPositive Net Change WSTNegative Net Change EXASNegative Net Change DOCSNegative Net Change
earnings medical medical-devices
Acadia Q3 Earnings Beat on Growing Volumes, Guidance Lowered
by Zacks Equity Research
ACHC beats Q3 estimates on stronger patient volumes, but rising costs and lower guidance remain concerning.
UHSPositive Net Change CYHPositive Net Change HCAPositive Net Change ACHCNegative Net Change
earnings medical
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down
by Zacks Equity Research
Esperion's Q3 loss widens despite a 69% jump in revenues. Mixed results and investor jitters probably drag ESPR shares down 15%.
RDYNegative Net Change ANIPPositive Net Change ESPRPositive Net Change ARQTNegative Net Change
earnings medical
Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales
by Zacks Equity Research
ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.
ALKSPositive Net Change ANIPPositive Net Change CRMDNegative Net Change ALLOPositive Net Change
biotechs earnings medical
Bet on These 4 Top-Performing Liquid Stocks to Maximize Returns
by Vaishali Doshi
EVER, FOLD, LRCX and CBOE make the cut as top liquid stocks, with each boasting strong liquidity, growth attributes and operational efficiency.
LRCXNegative Net Change CBOEPositive Net Change EVERPositive Net Change FOLDNegative Net Change
finance medical tech-stocks
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus
by Zacks Equity Research
Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.
RHHBYPositive Net Change BMYPositive Net Change NVONegative Net Change PRTAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.
LLYNegative Net Change NKTRPositive Net Change ANIPPositive Net Change ACADPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
by Zacks Equity Research
Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.
REGNPositive Net Change ANIPPositive Net Change ACADPositive Net Change NTLANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
SOLV Gains on Q3 Earnings & Sales Beat, Raises '25 EPS Outlook
by Zacks Equity Research
Solventum posts strong Q3 results with a revenue and earnings beat, lifts 2025 EPS guidance on solid MedSurg and HIS growth.
BSXPositive Net Change MCKNegative Net Change ALCNegative Net Change SOLVPositive Net Change
earnings medical medical-devices
Bet on These 5 Dividend Growth Stocks Amid Volatile Market
by Aparajita Dutta
Market volatility is rising, but dividend growth stocks like VRT, TPR and HCA may offer investors much-needed stability and upside potential.
LRCXNegative Net Change CBOEPositive Net Change HCAPositive Net Change TPRPositive Net Change VRTNegative Net Change
computers finance medical retail
Cannabis Stock Tilray Brands Skyrockets 94.5%: Time to Buy, Sell or Hold?
by Sridatri Sarkar
TLRY's 94.5% surge, record fiscal Q1 revenues, and expanding medical cannabis footprint fuel optimism amid global challenges.
TLRYPositive Net Change VFFNegative Net Change CURLFPositive Net Change
marijuana medical
4 Must-Buy Efficient Stocks to Enrich Your Portfolio in 2025
by Santanu Roy
INDV, PRLB, LVS and OII top Zacks' efficiency screen with strong margins and solid earnings surprises.
LVSPositive Net Change OIIPositive Net Change PRLBPositive Net Change INDVNegative Net Change
consumer-discretionary industrial-products medical oil-energy
Hologic's Breast Health Rebounds, Takes Spotlight in Buyout Deal
by Moumi Mondal
After a strong Q4 rebound, HOLX's Breast Health takes center stage in the company's upcoming private equity takeover.
BDXPositive Net Change HOLXNegative Net Change GEHCNegative Net Change
medical medical-devices
Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
by Zacks Equity Research
RVMD posts a wider Q3 loss as rising R&D and administrative costs weigh, while its RAS(ON) pipeline advances toward key 2026 data.
ALKSPositive Net Change ANIPPositive Net Change CRMDNegative Net Change RVMDNegative Net Change
biotechs earnings medical
QuidelOrtho Q3 Earnings and Revenues Beat Estimates, Margins Expand
by Zacks Equity Research
QDEL tops Q3 estimates as Labs and Immunohematology units drive growth, while margins strengthen despite respiratory revenue declines.
BSXPositive Net Change QDELNegative Net Change WSTNegative Net Change EXASNegative Net Change
earnings medical medical-devices
Inogen Stock Dips Despite Q3 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
INGN stock slid despite a narrower Q3 loss and rising B2B demand, as weaker consumer and rental sales weighed on results.
BSXPositive Net Change WSTNegative Net Change INGNNegative Net Change EXASNegative Net Change
earnings medical medical-devices
PACB Stock Down Despite Q3 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
PacBio posts a narrower Q3 loss and margin gains, but shares fall as revenues dip amid softer instrument demand.
BSXPositive Net Change WSTNegative Net Change PACBNegative Net Change EXASNegative Net Change
earnings medical medical-devices
CONMED Q3 Earnings and Revenues Beat Estimates, Margins Contract
by Zacks Equity Research
CNMD beats third-quarter 2025 estimates on strength in surgery segments, but gross and operating margins see sharp contraction.
BSXPositive Net Change CNMDNegative Net Change WSTNegative Net Change EXASNegative Net Change
earnings medical medical-devices
BD Stock Slips in Pre-Market Despite Q4 Earnings Beat, Margins Up
by Zacks Equity Research
BDX tops fourth-quarter fiscal 2025 earnings estimates and posts strong margin gains, with growth across all business segments and geographies.
BSXPositive Net Change BDXPositive Net Change WSTNegative Net Change EXASNegative Net Change
earnings medical medical-devices
Pediatrix Medical Q3 Earnings Beat Estimates on Declining Expenses
by Zacks Equity Research
MD's Q3 profit tops on lower expenses and improved patient acuity, driving earnings past estimates despite softer revenues.
UHSPositive Net Change MCKNegative Net Change MDPositive Net Change VCYTPositive Net Change
earnings medical